Last updated: 2026-09-16 10:32:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Organon & Co. (OGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $13.33, with a market capitalisation of $3.58B and a P/E ratio of 17.16. Over the past 52 weeks, its price has ranged from $5.69 to $13.79. This page covers its latest market performance, valuation, price trends and company information.
$3.58B | |
$13.65 | |
$39.48 | |
$5.69 | |
$13.66 | |
2.00 | |
2.78M | |
17.16 | |
$13.79 | |
$5.69 | |
0.50% | |
-- |
Organon & Co. (OGN) is trading at $13.33 in pre-market trading as of 2026-09-16 10:17:00, down 2.41% ($0.33) from the previous close of $13.66
Pre-market trading shows how investors are pricing OGN before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Organon & Co. (OGN) moved from $13.78 to $13.33, representing a decline of 3.26% ($0.45).
The stock traded between $13.33 and $13.78 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 2.96 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 94.4%
OGN is currently trading at $13.33, placing it 94.4% of the way from its 52-week low of $5.69 to its 52-week high of $13.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 10000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Organon & Co. (OGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.